Bicara Therapeutics Inc.
BCAX
$11.32
-$0.52-4.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -102.67M | -92.33M | -68.00M | -59.48M | -64.84M |
| Total Depreciation and Amortization | 68.00K | 62.00K | 56.00K | 55.00K | 42.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.30M | 9.70M | 7.32M | 5.86M | 17.64M |
| Change in Net Operating Assets | -10.65M | -5.70M | -14.13M | 807.00K | 1.10M |
| Cash from Operations | -100.96M | -88.27M | -74.75M | -52.76M | -46.06M |
| Capital Expenditure | -48.00K | -67.00K | -71.00K | -467.00K | -609.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 62.00K | 62.00K | 62.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -48.00K | -67.00K | -9.00K | -405.00K | -547.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 334.13M | 335.33M | 335.01M | 335.01M | 1.55M |
| Repurchase of Common Stock | -975.00K | -975.00K | -975.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 194.70M | 234.52M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 596.00K | 0.00 | 0.00 | 0.00 | -596.00K |
| Cash from Financing | 333.76M | 334.35M | 334.03M | 529.71M | 235.48M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 232.75M | 246.02M | 259.27M | 476.55M | 188.87M |